Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chemotherapy agent

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    899 result(s) found for: Chemotherapy agent. Displaying page 5 of 45.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-005174-68 Sponsor Protocol Number: UZL OFT-AMO 001 Start Date*: 2006-04-21
    Sponsor Name:UZLeuven Afdeling Oogziekten
    Full Title: A Double blind Interventional study exploring the efficacy of topical eye treatment in the prevention of Docetaxel induced Dacryostenosis.
    Medical condition: The rationale of this randomized double blind study is to investigate the efficacy of topical eye treatment in patients on a weekly Docetaxel regimen in prevention of dacryostenosis. The dacryotoxi...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003761-17 Sponsor Protocol Number: RADAR-1CRPC Start Date*: 2020-04-02
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: A RAndomized, open label, multicenter study of Docetaxel versus an Androgen Receptor-targeted agent (abiraterone or enzalutamide) as first-line of therapy in mCRPC patients with adverse prognostic ...
    Medical condition: Castration resistant prostate cancer docetaxel and androgen receptor-targeted agent (abiraterone or enzalutamide) naïve.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022742-25 Sponsor Protocol Number: TS-P04832 Start Date*: 2012-04-16
    Sponsor Name:Tesaro, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects ...
    Medical condition: Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10049091 Chemotherapy antiemetic prophylaxis LLT
    14.1 10042613 - Surgical and medical procedures 10054133 Prophylaxis of nausea and vomiting PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) BE (Completed) PT (Completed) BG (Completed) ES (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2005-005547-26 Sponsor Protocol Number: MDX060-04 Start Date*: 2007-03-13
    Sponsor Name:Medarex, Inc.
    Full Title: An Open-label, Fixed-dose, Multicenter, Phase II Study of MDX-060 in Patients with Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma
    Medical condition: Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma (ALCL)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001094-15 Sponsor Protocol Number: CDBC1 Start Date*: 2006-09-04
    Sponsor Name:Oxford Radcliffe Hospitals NHS Trust (Cancer Research UK Medical Oncology Unit, Churchill Hospital)
    Full Title: Dose-banding of carboplatin: Effect on area under the plasma concentration - time curve (AUC) compared with individualised dosing
    Medical condition: Conditions for which carboplatin is indicated for: 1. Advanced ovarian carcinoma of epithelial origin in: - first line therapy - second line therapy, after other treatments have failed. 2. Small ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004493-26 Sponsor Protocol Number: D9670C00001 Start Date*: 2020-09-02
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) versus Investigator’s Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients whose...
    Medical condition: HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed on Endocrine Therapy in the Metastatic Setting.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) PT (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004009-24 Sponsor Protocol Number: GOIRC 02/2006 Start Date*: 2006-12-12
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA
    Full Title: Randomized phase II study of pemetrexed versus pemetrexed and carboplatin as second line chemotherapy in advanced non-small-cell lung cancer (NSCLC).
    Medical condition: Previously treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007827-14 Sponsor Protocol Number: PALO-08-09 Start Date*: 2009-11-24
    Sponsor Name:Helsinn Healthcare SA
    Full Title: Multicenter, Phase IV, Open-Label, Uncontrolled Study to Assess the Efficacy and Safety of a Single Intravenous Dose of Palonosetron 0.25 mg (Aloxi®, Onicit®, Paloxi®) in the Prevention of Chemothe...
    Medical condition: Prevention of moderately emetogenic CINV in up to four repeated and consecutive single-day MEC cycles administered to patients with Non-Hodgkin’s Lymphomas.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10042613 - Surgical and medical procedures 10054133 Prophylaxis of nausea and vomiting PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001006-28 Sponsor Protocol Number: 20170770 Start Date*: 2019-09-13
    Sponsor Name:Amgen Inc.
    Full Title: PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of No...
    Medical condition: non-small cell lung cancer (NSCLC), ovarian cancer, or breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) AT (Completed) HU (Completed) ES (Ongoing) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000931-28 Sponsor Protocol Number: GEXMab25201 Start Date*: 2013-06-25
    Sponsor Name:Glycotope GmbH
    Full Title: A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEX™ After Chemotherapy in Patients With Recurrent Epithelial ...
    Medical condition: Recurrent Epithelial Ovarian Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) DE (Prematurely Ended) HU (Prematurely Ended) ES (Completed) GB (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001718-41 Sponsor Protocol Number: 0517-31 Start Date*: 2012-09-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of...
    Medical condition: chemotherapy induced nausea and vomiting
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NL (Completed) ES (Completed) CZ (Completed) SE (Completed) HU (Completed) IT (Completed) PT (Completed) LV (Completed) PL (Completed) BG (Completed) GR (Completed) NO (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2009-012504-13 Sponsor Protocol Number: A8081005 Start Date*: 2010-01-20
    Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY10017
    Full Title: PHASE 2, OPEN-LABEL SINGLE ARM STUDY OF THE EFFICACY AND SAFETY OF PF 02341066 IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION INVOLVING THE ANAP...
    Medical condition: metastatic non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) DE (Completed) ES (Completed) HU (Completed) PL (Completed) GR (Completed) IT (Completed) FR (Completed) IE (Completed) BG (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004957-24 Sponsor Protocol Number: FM-B04-01 Start Date*: 2005-04-27
    Sponsor Name:FONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI
    Full Title: EUROPEAN COOPERATIVE STUDY OF PRIMARY SYSTEMIC THERAPY IN WOMEN WITH OPERABLE BREAST CANCER AND T < 2 CM
    Medical condition: Primary systemic therapy in operable breast cancer < 2 cm
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) AT (Completed) ES (Ongoing) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001655-39 Sponsor Protocol Number: GCT1015-07 Start Date*: 2021-08-17
    Sponsor Name:Genmab A/S
    Full Title: A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin Versus Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
    Medical condition: Second- or Third-Line Recurrent or Metastatic Cervical Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008342 Cervix carcinoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) NO (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) DK (Completed) NL (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-002600-33 Sponsor Protocol Number: IBCSG 34-05/ SWOG 0230 Start Date*: 2007-02-16
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: Phase III trial of LHRH analog administration during chemotherapy to reduce ovarian failure following chemotherapy in early stage, hormone-receptor negative breast cancer
    Medical condition: Premenopausal women, Early Stage I, II or IIIA, ER-/ PR- Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-000189-45 Sponsor Protocol Number: Start Date*: 2018-03-26
    Sponsor Name:University of Padova
    Full Title: Adjuvant treatment for high-risk triple negative breast cancer patients with the anti-pd-l1 antibody Avelumab: A phase III randomized trial
    Medical condition: High risk triple negative (ER negative, PR negative, HER2 negative) breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004475-75 Sponsor Protocol Number: IFCT-1501 Start Date*: 2016-02-08
    Sponsor Name:IFCT
    Full Title: A randomized phase II study evaluating efficacy and safety of 2nd or 3rd line treatment by Nivolumab monotherapy or Nivolumab plus Ipilimumab, for unresectable Malignant Pleural Mesothelioma (MPM) ...
    Medical condition: Malignant Pleural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-002714-11 Sponsor Protocol Number: EORTC 22033-26033 Start Date*: 2005-06-06
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study
    Medical condition: Histologically proven low-grade glioma ♦ Astrocytoma WHO grade II (gemistocytic, fibrillary and protoplasmatic) ♦ Oligoastrocytoma WHO grade II ♦ Oligodendroglioma WHO grade II
    Disease: Version SOC Term Classification Code Term Level
    7.1 10025783 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) GB (Completed) IT (Completed) DK (Prematurely Ended) BE (Completed) ES (Completed) PT (Completed) HU (Completed) SE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2012-003530-16 Sponsor Protocol Number: PM0259CA231B0 Start Date*: 2012-11-14
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Randomised phase II study evaluating, as first-line chemotherapy, weekly oral vinorelbine as a single-agent versus weekly paclitaxel as a single-agent in estrogen receptor positive, HER2 negative p...
    Medical condition: advanced breast cancer with estrogen receptor positive and HER2 negative.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) ES (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-004207-13 Sponsor Protocol Number: Toco-CoR Start Date*: 2019-12-11
    Sponsor Name:Vejle Hospital
    Full Title: Tocotrienol and Bevacizumab in metastatic colorectal cancer. A randomized phase II marker trial
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 20 07:26:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA